AstraZeneca PLC
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pascal Claude Roland Soriot
- Full Time Employees
- 96,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge CA United Kingdom CB2 0AA
- IPO Date
- May 12, 1993
- CIK
- 0000901832
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company dedicated to the discovery, development, production, and worldwide commercialization of innovative prescription medicines. The company maintains a comprehensive portfolio of treatments spanning key therapeutic areas, including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, rare disease, and vaccines and immune therapies. Its innovative products serve a global patient population, reaching over 125 countries through a network of local marketing companies, distributors, and representative offices. The firm's operational focus centers on pioneering scientific breakthroughs to address significant unmet medical needs. AstraZeneca actively invests in research and development, evidenced by substantial annual expenditures aimed at advancing a robust pipeline of next-generation therapies. Recent strategic initiatives include ambitious goals for revenue growth, with an aim to launch 20 new medicines and achieve $80 billion in total revenue by 2030. AstraZeneca consistently engages in strategic partnerships and acquisitions to bolster its capabilities and pipeline. Notable collaborations include an expanded alliance with Harbour BioMed for next-generation biotherapeutics and a research agreement with CSPC Pharmaceutical Group for novel oral drug candidates. The company also recently invested $2 billion in a new Maryland manufacturing facility to establish cell therapy platforms, and its digital health solutions arm, Evinova, was launched in late 2023. Recent product advancements and approvals include Koselugo for neurofibromatosis type 1 in adults and positive Phase III results for Baxdrostat in resistant hypertension. AstraZeneca was established through the merger of Astra AB and Zeneca Group in 1999, and its headquarters are situated in Cambridge, United Kingdom.
Company News
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum
NTHM's Index Rebalance Puts Thematic Rotation to Work
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
QRG Capital Management Inc. Buys 8,023 Shares of Astrazeneca Plc $AZN
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
Polaris Rx Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service for Second Consecutive Year
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
First Look: Fed Hikes Rates, Amazon-Generac Deal, AI & Energy Updates
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England
AstraZeneca Shares Rise as J.P. Morgan Stays Overweight
Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?
First Look: Fed Rate Hike Looms, Ford Unveils 2027 F-150, Paramount-WBD Antitrust Talks
AstraZeneca (LON:AZN) Insider Michel Demare Buys 2,500 Shares of Stock
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?